6 patents
Utility
Antibody cocktail against SARS-CoV-2 spike protein
5 Dec 23
Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject.
Matthew K. Robinson, Pavel Nikitin, Michael John Morin, Jillian Dimuzio, Ray Howanski, John P. Dowling
Filed: 4 Jan 22
Utility
IL-38-SPECIFIC Antibodies
1 Sep 22
This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof.
Matthew K. ROBINSON, Karen LUNDGREN, Ben HARMAN, Pavel A. NIKITIN, John P. DOWLING
Filed: 30 Jul 20
Utility
Antibody Cocktail Against SARS-COV-2 Spike Protein
28 Jul 22
Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject.
Matthew K. ROBINSON, Pavel NIKITIN, Michael John MORIN, Jillian DIMUZIO, Ray HOWANSKI, John P. DOWLING
Filed: 4 Jan 22
Utility
Antibodies Targeting EPN1
6 Jan 22
Described herein, are antibodies specific for epsin-1 (EPN1), an antigen expressed on the surface of various cancer cells.
Matthew K. ROBINSON
Filed: 2 Oct 19
Utility
Exosome-targeting Bispecific Antibodies
11 Nov 21
The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 (“PD-L1”) as a second exosome-associated protein.
Matthew K. ROBINSON, Michael John MORIN
Filed: 17 Oct 19
Utility
CH3 Domain Epitope Tags
22 Jul 21
This invention relates to the incorporation of one, or more, heterologous antibody epitopes into the AB, EF, or CD structural loops of the constant heavy domain 3 (“CH3 domain”) of an engineered antibody or Fc-linked therapeutic agent.
Matthew K. ROBINSON, Michael John MORIN
Filed: 17 May 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first